Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 1, 2011, Pages 77-83

  Jeon, Christie Y ^a   Calver, A D ^b   Victor, T C ^c   Warren, R M ^c   Shin, S S ^d   Murray, M B ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Anglogold Ashanti Health West Vaal Hospital   (South Africa)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug resistant TB; Fluoroquinolone; Smear microscopy; Treatment delay; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GOLD; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACID FAST BACTERIUM; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GYRA GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MINER; MINING; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOUTH AFRICA; SPUTUM SMEAR; THERAPY DELAY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; DNA GYRASE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GOLD; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MINING; MUTATION; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SOUTH AFRICA; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 78650109516     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. World Health Organization. Global tuberculosis database. Geneva, Switzerland: WHO, 2009. http://apps.who.int/global atlas/ dataQuery/default.asp Accessed October 2010.
2. Pletz M W, De Roux A, Roth A, Neumann K H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780-782. (Pubitemid 38280324)
3. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066-2069.
4. Gillespie S H, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44: 393-395.
5. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
6. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751. (Pubitemid 30152215)
7. Burman W J, Goldberg S, Johnson J L, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338. (Pubitemid 44156613)
8. Guthrie R. Community-acquired lower respiratory tract infections: etiology and treatment. Chest 2001; 120: 2021-2034. (Pubitemid 34053469)
9. Huang E S, Stafford R S. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 2002; 162: 41-47.
10. Andriole V T. The quinolones: past, present, and future. Clin Infect Dis 2005; 41(Suppl 2): S113-S119.
11. Vaccheri A, Silvani M C, Bersaglia L, et al. A 3 year survey on the use of antibacterial agents in five Italian hospitals. J Antimicrob Chemother 2008; 61: 953-958. (Pubitemid 351426084)
12. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009; 48: 1354-1360.
13. Danish Integrated Antimicrobial Resistance Monitoring and Research Programme. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. Copenhagen, Denmark: DANMAP, 2007.
14. Gaba P D, Haley C, Griffin M R, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007; 167: 2317-2322. (Pubitemid 350179526)
15. Dooley K E, Golub J, Goes F S, Merz W G, Sterling T R. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607-1612. (Pubitemid 34615446)
16. Yoon Y S, Lee H J, Yoon H I, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005; 9: 1215-1219.
17. Wang J Y, Hsueh P R, Jan I S, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
18. Osawa N, Sakaguchi M, Sugimoto T, et al. Does empiric treatment with fluoroquinolones delay the diagnosis of tuberculosis in patients with hemodialysis? Hemodial Int 2008; 12: 499-500.
19. Golub J E, Bur S, Cronin W A, et al. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2005; 9: 392-397. (Pubitemid 40524029)
20. Chang K C, Leung C C, Yew W W, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur Respir J 2010; 35: 606-613.
21. Devasia R A, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180: 365-370.
22. Ginsburg A S, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-1452. (Pubitemid 37494671)
23. Department of Health, South Africa. Draft - tuberculosis strategic plan for South Africa, 2007-2011. Pretoria, South Africa: DoH. http://www.doh.gov.za/ tb/index.html Accessed November 2010.
24. Corbett E L, Charalambous S, Fielding K, et al. Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis 2003; 188: 1156-1163.
25. Eisler R. Health risks of gold miners: a synoptic review. Environ Geochem Health 2003; 25: 325-345.
26. Cheng A F, Yew W W, Chan E W, Chin M L, Hui M M, Chan R C. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
27. Park I N, Hong S B, Oh Y M, et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007; 11: 319-324.
28. Grimaldo E R, Tupasi T E, Rivera A B, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.
29. Agrawal D, Udwadia Z F, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13: 79-83.
30. Jeon C Y, Hwang S H, Min J H, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008; 46: 42-49.
31. Huang T S, Kunin C M, Shin-Jung Lee S, Chen Y S, Tu H Z, Liu Y C. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995- 2003. J Antimicrob Chemother 2005; 56: 1058-1062.
32. Wang J Y, Lee L N, Lai H C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007; 59: 860-865.
33. Xu P, Li X, Zhao M, Gui X, et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 2009; 53: 3170-3172.
34. Post F A, Willcox P A, Mathema B, et al. Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. J Infect Dis 2004; 190: 99-106.
35. Takiff H E, Cimino M, Musso M C, et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996; 93: 362-366.